Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vaxcyte, Inc. announced that director Heath Lukatch will retire from its Board of Directors effective July 16, 2026, after more than eight years of service. His retirement is stated to not result from any disagreement or dispute with the company.
On the same date, the Board appointed John Markels as a Class II director, with a term expiring at the 2028 annual meeting of stockholders, and named him to the Audit Committee and Compensation Committee. The Board determined he qualifies as an independent director under Nasdaq Rule 5605(a)(2). He will be compensated under the company’s non-employee director compensation program, under which the equivalent value of the annual equity grant for all directors is currently $430,000, and has entered into the company’s standard indemnification agreement.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Retirement effective date: July 16, 2026
New director term end: 2028
Board service length: more than eight years
+1 more
4 metrics
Retirement effective date
July 16, 2026
Effective date of Heath Lukatch’s retirement from the Board of Directors
New director term end
2028
Year of the annual meeting of stockholders when John Markels’ term as Class II director expires
Board service length
more than eight years
Approximate duration of Heath Lukatch’s service on Vaxcyte’s Board
Annual equity grant value
$430,000
Equivalent value of the annual equity grant for all directors under the Director Compensation Program
Key Terms
Class II director, independent director, Nasdaq Rules, Item 404(a) of Regulation S-K, +1 more
5 terms
Class II director regulatory
"appointed John Markels to the Board as a Class II director"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
independent director regulatory
"The Board has determined that Dr. Markels qualifies as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Nasdaq Rules regulatory
"under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules"
Nasdaq rules are a set of guidelines and requirements that companies must follow to be listed and remain on the Nasdaq stock exchange. These rules help ensure companies are transparent, financially healthy, and operate fairly, which is important for investors to trust the market and make informed decisions. Think of them as the standards that keep the marketplace honest and organized.
Item 404(a) of Regulation S-K regulatory
"the Company would be required to report pursuant to Item 404(a) of Regulation S-K"
indemnification agreement regulatory
"The Company has entered into its standard form of indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
FAQ
What board change did Vaxcyte (PCVX) disclose regarding Heath Lukatch?
Vaxcyte reported that Heath Lukatch notified its Board of his retirement, effective July 16, 2026, after more than eight years of service. The company stated that his retirement was not due to any disagreement or dispute with Vaxcyte.
Who is the new director appointed to Vaxcyte’s (PCVX) board and what is his term?
Vaxcyte appointed John Markels as a Class II director, effective July 16, 2026. His term will expire at the company’s 2028 annual meeting of stockholders, aligning him with the director class that stands for election in 2028.
Is Vaxcyte’s (PCVX) new director John Markels considered independent?
The Board determined that John Markels qualifies as an independent director under the independence requirements in Nasdaq Rule 5605(a)(2). The company also stated there are no reportable related-party transactions with him under Item 404(a) of Regulation S-K.
What committees will John Markels serve on at Vaxcyte (PCVX)?
Vaxcyte’s Board appointed John Markels to its Audit Committee and Compensation Committee. These assignments place him in key oversight roles covering the company’s financial reporting processes and its executive and director compensation programs.
How will Vaxcyte (PCVX) compensate new director John Markels?
John Markels will receive compensation under Vaxcyte’s non-employee director compensation program. The company noted that the equivalent value of the annual equity grant for all directors under this program is currently $430,000, plus standard indemnification protection.